InNexus Biotechnology CEO To Present at BioContactQuebec 2008

---Receives Recognition in Two Leading Industry Publications---

BRITISH COLUMBIA, CANADA - September 29, 2008 - InNexus Biotechnology Inc, (TSX VENTURE: IXS, OTCBB: IXSBF, http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology, announces Jeff Morhet, CEO and Chairman, to present during BioContactQuebec 2008. The company also announces the featuring of Mr. Morhet in two leading publications, Genetic Engineering & Biotechnology News and The PharmaVoice List of Top 100 in Life Sciences.

During BioContactQuebec 2008, InNexus' CEO will present on Thursday, October 2nd at 2:30-3:00 PM EDT on the Salle Lavel at the Chateau Frontenac, Quebec. The presentation will include a company overview and information about InNexus' unique business strategy, its DXL technology platform and upcoming company milestones. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the symposium.

Also announced, the most recent edition of Genetic Engineering & Biotechnology News features InNexus CEO Morhet in the article, Peptide Drugs Becoming More Prevalent, where he discusses the pharmaceutical industry and outlines InNexus' DXL antibody enhancement technology platform. Link to article.

The company also announced Mr. Morhet has also been named to PharmaVOICE's list of the "100 Most Inspiring People in the Life Sciences", July/August Edition. The publication illustrates those individuals who think outside the box, pioneering new paths to success and inspire their colleagues in the industry. PharmaVOICE Website.

About InNexus

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements.

Contact:

Wade Brooksby

Chief Financial Officer

InNexus Biotechnology Inc.

480-862-7500